Rare Partners (Italy)

Recent papers from Rare Partners (Italy)

1. Identifying Predictors of Early Treatment Intensification in Individuals With Type 2 Diabetes Treated With GLP ‐1 Receptor Agonists: A Machine Learning–Based Analysis of a Large Real World CohortDiabetes Obesity and Metabolism · 2026
2. Challenges and opportunities for women in vascular surgery: Summary from an international roundtable discussionJVS-Vascular Insights · 2025
3. Decrease in α-Globin and Increase in the Autophagy-Activating Kinase ULK1 mRNA in Erythroid Precursors from β-Thalassemia Patients Treated with SirolimusInternational Journal of Molecular Sciences · 2023
4. The Long Scientific Journey of Sirolimus (Rapamycin): From the Soil of Easter Island (Rapa Nui) to Applied Research and Clinical Trials on β-Thalassemia and Other HemoglobinopathiesBiology · 2023
5. A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established DrugsWellcome Open Research · 2022
6. β-sitosterol ameliorates inflammation and Pseudomonas aeruginosa lung infection in a mouse modelJournal of Cystic Fibrosis · 2022
7. A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established DrugsWellcome Open Research · 2022
8. A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established DrugsWellcome Open Research · 2022
9. Expression of γ-globin genes in β-thalassemia patients treated with sirolimus: results from a pilot clinical trial (Sirthalaclin)Therapeutic Advances in Hematology · 2022
10. Expression of γ-globin genes in β-thalassemia patients treated with sirolimus: results from a pilot clinical trial (Sirthalaclin)2021
11. Leverage and NAV discount: evidence from Italian real estate investment fundsJournal of European real estate research · 2009